Company intelligence / Profile preview
Clarus Biologics
Chapel Hill, North Carolina, USAclarusbiologics.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
Clarus Biologics develops next-generation vaccine technologies, focusing on proprietary virus-like particle-based adjuvants designed to enhance the safety, efficacy, and availability of vaccines. Their lead product has demonstrated significant preclinical safety and efficacy across multiple models but has not yet entered clinical trials. The company aims to license its technology to vaccine manufacturers globally and supply the adjuvant for commercial use.
- Therapeutic areas
- OtherInfectious Diseases
- Modalities
- Virus-Like Particles (VLPs)Vaccine adjuvants
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Clarus Biologics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Clarus Biologics.